Radar Signals: Ceragon Networks (CRNT) Large Orders, Alnylam

Ceragon Networks Ltd. (CRNT)

CRNT reported that it has received large orders from two leading national operators in North America and India. CRNT will deliver several thousand of its ultra-high capacity, SDN-ready IP-20-based solutions to these operators.

These advanced systems will be used to build wireless backhaul networks in support of each operator's plan to rollout extensive, nationwide 4G/LTE networks over the next few years.

CRNT 's IP-20 is a service-centric, SDN-ready wireless platform containing a rich product line for backhaul and fronthaul. Built around a powerful software-defined engine, the IP-20 platform supports any radio transmission technology mix, any network topology and any configuration.

CRNT provides innovative, flexible and cost-effective wireless backhaul and fronthaul solutions that enable mobile operators and other wired/wireless service providers to deliver 2G/3G, 4G/LTE and other broadband services to their subscribers.

More about Ceragon Networks Ltd. (CRNT) at www.ceragon.com

**

Crown Equity Holdings Inc. (CRWE)

Social networking is based on a certain structure that allow people to both express their individuality and meet people with similar interests. This structure includes having profiles, friends, blog posts, widgets, and usually something unique to that particular social networking website.

CRWE is looking to deliver value for its stockholders in both the near and long term, targeting the multi-billion dollar social networking service market.

CRWE is currently developing a social networking service and phone app, CRWE Network ( CRWE-PR.com ), that is designed to target all the communities in every state of the United States, with its geographic focus starting in Southern California and Las Vegas Nevada.

CRWE Network Travel Search is an information source for travelers searching for hotels, airline tickets, car rentals, cruise deals, Las Vegas events tickets and U.S. vacation rentals, to find the cheapest vacations online

CRWE ‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Alnylam Pharmaceuticals, Inc. (ALNY)

Genzyme and ALNY reported that they have significantly expanded their strategic agreement to develop and commercialize treatments for rare genetic diseases.

Genzyme will have significant rights to ALNY ’s portfolio of clinical and pre-clinical stage drug candidates. ALNY will retain most product rights in North America and Western Europe, and will have significantly expanded development and commercial opportunities for its genetic medicine pipeline through Genzyme’s established global infrastructure in rare diseases.

Genzyme will become a major ALNY shareholder with a stake of approximately 12% percent through a $700 million investment at a price of approximately $80 per share .

ALNY will receive R&D funding, starting on January 1, 2015, for programs where Genzyme has elected to opt-in for development and commercialization. ALNY also is eligible to receive milestones and royalties.

Furthermore, ALNY has raised its guidance to end 2013 with approximately $350 million in cash.

ALNY continues to lead the translation of RNAi therapeutics as a new class of medicines. The company has acquired Merck’s wholly owned subsidiary Sirna Therapeutics, Inc., comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies.

ALNY is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. ALNY 's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

More about Alnylam Pharmaceuticals, Inc. (ALNY) at www.alnylam.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer